Omalizumab biosimilar - Oneness Biotech
Alternative Names: FB-317Latest Information Update: 28 Feb 2023
At a glance
- Originator Academia Sinica
- Developer Oneness Biotech
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic asthma; Chronic urticaria
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Chronic-urticaria in China
- 28 Feb 2021 No recent reports of development identified for phase-I development in Allergic-asthma in China
- 10 Dec 2014 Phase-I clinical trials in Allergic asthma in China (unspecified)